Capricor Therapeutics (NASDAQ:CAPR) Downgraded by Zacks Investment Research to “Sell”

Zacks Investment Research downgraded shares of Capricor Therapeutics (NASDAQ:CAPRGet Rating) from a hold rating to a sell rating in a research report released on Monday, Zacks.com reports.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Several other research analysts have also recently weighed in on the company. HC Wainwright boosted their target price on Capricor Therapeutics from $14.00 to $18.00 and gave the stock a buy rating in a report on Monday, January 31st. StockNews.com initiated coverage on Capricor Therapeutics in a report on Thursday, March 31st. They set a sell rating on the stock.

CAPR stock opened at $3.09 on Monday. Capricor Therapeutics has a 12-month low of $2.56 and a 12-month high of $6.22. The business’s 50-day moving average is $3.72 and its 200 day moving average is $3.61.

Capricor Therapeutics (NASDAQ:CAPRGet Rating) last posted its quarterly earnings data on Thursday, March 10th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.07). During the same period in the prior year, the business posted ($0.21) earnings per share. As a group, analysts expect that Capricor Therapeutics will post -1.1 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in CAPR. Barclays PLC raised its position in Capricor Therapeutics by 246.1% in the third quarter. Barclays PLC now owns 6,330 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 4,501 shares during the period. Two Sigma Securities LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter worth $46,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Capricor Therapeutics during the first quarter worth $51,000. Goldman Sachs Group Inc. purchased a new stake in shares of Capricor Therapeutics during the third quarter worth $89,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Capricor Therapeutics during the third quarter worth $115,000. 9.49% of the stock is currently owned by institutional investors.

About Capricor Therapeutics (Get Rating)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Further Reading

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.